First Patient Dosed in Phase 2a Trial of NLX-112 for the Treatment of L-DOPA Induced Dyskinesia
November 30, 2021 Neurolixis, a clinical-stage biopharmaceutical company focused on advancing novel therapies to treat central nervous...
Professor Howard Federoff joins Board of Vivifi Biotech
24 September 2021 Parkinson’s Virtual Biotech is pleased to announce the appointment of world-leading Parkinson’s expert, Professor...
Parkinson’s UK invests further £490K in NRG Therapeutics Parkinson’s Drug Discovery Programme
Cambridge, UK, 23 August 2021 - NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial...
NRG Therapeutics Awarded $500K Grant from The Michael J. Fox Foundation
Wednesday 29 July 2021 - NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial...
Parkinson’s UK Implements CDD Vault to Manage Its Pioneering Drug Discovery Data
London and San Francisco, July 19, 2021 - Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, has announced...
UK charity announces £1.2 million funding to design Parkinson’s drug
Tuesday 09 March 2021 - Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, is investing up to £1.2 million...